Psychosis associated with bupropion treatment

American Journal of Psychiatry (Impact Factor: 13.56). 01/1986; 142(12):1459-62.
Source: PubMed

ABSTRACT The authors describe the development of acute psychoses in four patients treated with bupropion, a unicyclic aminoketone antidepressant. In two of the cases the psychoses seemed to be affected by dose. The mechanism responsible for the psychotic reactions is unclear, although it may involve perturbation of dopaminergic systems. On the basis of their experience, the authors offer recommendations regarding the clinical use of bupropion.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Bupropion is a newer antidepressant with the main pharmacological effects of dopamine and norepinephrine reuptake inhibition. The usage of bupropion is relatively safe with minor side effects. In some rare instances, psychosis and delirium may emerge because of its potentiating effects on dopaminergic neurotransmission. Here we presented a case of bupropion SR (300mg/day) related to delirium with concurrent quetiapine (400mg/day) usage. Although there are fewer side effect profiles of bupropion SR, our case revealed acute delirium after administration of a therapeutic dosage of bupropion. Poor cytochrome P450 2D6 (CYP2D6) and cytochrome P450 2B6 (CYP2B6) metabolism and underlying bipolarity may contribute to this adverse effect. Clinicians should be cautioned when prescribing bupropion SR to vulnerable populations.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Visual hallucinations occur in diverse clinical circumstances including ophthalmologic diseases, neurologic disorders, toxic and metabolic disorders and idiopathic psychiatric illnesses. Their content, duration and timing relate to their cause and provide useful differential diagnostic information. Hallucinations must be distinguished from delusions and confabulation. A systematic approach to differentiating among hallucinatory syndromes may improve diagnostic accuracy.
    Western Journal of Medicine 02/1987; 146(1):46-51.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The authors performed a double-blind study in which 38 inpatients diagnosed as schizophrenic with depressive symptoms were treated with either bupropion and thiothixene or placebo and thiothixene. Of the 36 patients who completed 4 weeks of study treatment, the placebo-thiothixene treated patients did significantly better than the bupropion-thiothixene treated patients on BPRS total scores as well as anxiety and depression items. The bupropion-thiothixene treated patients reported significantly more dry mouth and constipation than the placebo-thiothixene treated group, whereas the placebo-thiothixene treated group reported more frequent occurrences of increased appetite, menstrual disturbance, and decreased sex drive. Neither group differed on ratings of pseudoparkinson or dyskinetic signs. The antidepressant bupropion as an adjunct to thiothixene was less effective in the treatment of depressed schizophrenic patients than the antipsychotic alone and appeared to inhibit the therapeutic effects of thiothixene primarily in the depressive symptoms of the syndrome.
    Drug Development Research 01/1988; 12(3‐4):259 - 266. DOI:10.1002/ddr.430120308 · 0.73 Impact Factor
Show more